ClinicalTrials.gov
public full text
Public Domain
An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
The primary objective is to study changes in disease related biomarkers in patients with progressive SSc during treatment with ABR-215757. The secondary objectives are to assess the safety and tolerability of ABR-215757,to assess disease activity and quality of life (QoL)during treatment with ABR-215757 and to assess the plasma levels of ABR-215757 during the study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- What is the Optimal Follow-up for Patients With Systemic Sclerosis?#889084
- A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.#1307950
- Metabolomic Analysis of Systemic Sclerosis#825876
- A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics#1230751
- A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People#1259618
Record · ID 1372706
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive